March 25, 2017 6:48 PM ET


Company Overview of X-Chem, Inc.

Company Overview

X-Chem, Inc. operates independently of Pharmaceutical Product Development, LLC as of January 06, 2016.

100 Beaver Street Suite 101

Waltham, MA 02453

United States





Key Executives for X-Chem, Inc.

X-Chem, Inc. does not have any Key Executives recorded.

X-Chem, Inc. Key Developments

Ono Pharmaceutical Co., Ltd. Enters into Collaboration Agreement with X-Chem, Inc

Ono Pharmaceutical Co., Ltd. announced that Ono and X-Chem, Inc. signed a collaboration agreement, focused on discovering novel small molecules targeting multiple promising, high-impact oncology targets. Under the agreement, Ono will pay to X-Chem an upfront payment, research and license fees, success-based milestones on the research and development progress, as well as royalties on sales of the products. X-Chem will apply their proprietary DEX TM libraries, which contain over 120 billion small molecules, toward the discovery of new drug leads against multiple oncology targets selected by Ono. Ono will have worldwide exclusive rights to develop and commercialize any pharmaceutical products arising out of the drug discovery collaboration.

X-Chem, Inc. Announces Strategic Collaboration with Astellas Pharma Across Multiple Therapeutic Areas

X-Chem, Inc. announced the signing of a broad drug discovery collaboration with Astellas Pharma Inc. (Astellas). The collaboration will enable the discovery of novel lead compounds for complex drug targets of interest to Astellas from X-Chem’s growing collection of DNA-encoded DEXTM libraries containing over 120 billion compounds. This new partnership is X-Chem’s expansive first-time alliance with a pharmaceutical company, and is aimed at tackling hard-to-drug targets across multiple therapeutic areas at Astellas. Under the terms of this multi-year agreement, X-Chem will receive an up-front payment of $16 million. X-Chem is eligible to receive research funding, as well as license and option fees as the drug discovery collaboration proceeds. Additionally, Astellas has the option to license compounds identified through this collaboration, and X-Chem will be entitled to pre-clinical, developmental, and commercial milestone payments on licensed compounds against each target. Milestone payments could amount to over $100 million per target, in addition to royalties based on sales of future products.

X-Chem, Inc. Expands Collaboration with Janssen Biotech, Inc. to Discover New Drug

X-Chem, Inc. announced that it has expanded its collaboration with Janssen Biotech, Inc. to discover new drug leads for the treatment of inflammatory disease. The multi-target expansion builds on the parties' existing discovery and license partnership, entered into in December 2014, and was facilitated by Johnson & Johnson Innovation. This latest agreement will apply X-Chem's DEX platform to the identification of novel modulators for challenging disease targets, following the licensing of multiple series of X-Chem-discovered small molecules by Janssen in 2016. Under the terms of the agreement, X-Chem receives an upfront payment and research funding, and is eligible to receive additional payments and royalties based on the achievement of clinical, regulatory and commercial milestones.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact X-Chem, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at